logo-loader
viewOrgenesis

Orgenesis and ExcellaBio develop a breakthrough manufacturing process for bioxomes

The companies have demonstrated the optimization and scale-up of bioxomes, while generating consistent and repeatable results

Orgenesis -
Bioxomes are engineered and produced through a patented method as membrane nanoparticles isolated from cell cultures of various sources, said the company

Orgenesis Inc (NASDAQ:ORGS) announced Tuesday a breakthrough in the field of cell and gene therapy.

In a statement, the global biotech said it had "developed a breakthrough and patented manufacturing process" for so-called bioxomes, through its collaboration and licensing agreement with ExcellaBio Ltd.

READ: Orgenesis CEO Vered Caplan says R&D labs still operating during coronavirus pandemic

Bioxomes are synthetically made exosomes or extracellular vesicles (EVs). The latter are what transfers DNA, RNA, and proteins to other cells, thereby altering the function of targeted cells.

Bioxomes are engineered and produced through a patented method as membrane nanoparticles isolated from cell cultures of various sources, said the company

"Orgenesis and ExcellaBio have now demonstrated the optimization and scale up of bioxomes, while generating consistent and repeatable results, including uniform particles sizes," it added

Until now, exosome/EV production has been based on conventional, complex and costly methods of ultracentrifugation or ultrafiltration.

Huge breakthrough

"Orgenesis and ExcellaBio developing this new process represents a true breakthrough in the field of cell and gene therapy," said Orgenesis CEO Vered Caplan in a statement.

"It provides the ability to produce robust yields in only a few steps. We believe this process may unlock the potential for large-scale production of bioxomes for a variety of therapeutic applications based on the natural intracellular trafficking abilities of exosomes/ EVs. In particular, we are aiming to develop promising new therapies, where we can deliver intracellular antiviral payloads, among dozens of other potential cell and gene therapies," she added.

Bioxomes can be sourced effectively from various cell cultures. These include mesenchymal stem cells, immortalized cells, immune cells and epithelial cells, the firm added.

Shares added nearly 10% to $3.64 in New York

---Updates for share price---

Contact the author at [email protected]

Quick facts: Orgenesis

Price: 6.985 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $153.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read